| Aktie | Ticker | Breite | GCS | 2025/Q3 | |||
|---|---|---|---|---|---|---|---|
| Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | ||||
| 16.369.175 $ | +10.718.167 $ | +124,1 % | 8 | ||||
| Ovid Therapeutics Inc. | OVID | → 0 | Neutral | 9.791.595 $ | +7.306.215 $ | +294,0 % | 1 |
| Equillium, Inc. | EQ | → 0 | Neutral | 2.609.717 $ | +2.034.484 $ | +353,7 % | 1 |
| Xilio Therapeutics, Inc. | XLO | → 0 | Stark | 1.243.084 $ | +240.149 $ | +23,9 % | 1 |
| Shattuck Labs, Inc. | STTK | → 0 | Neutral | 1.232.329 $ | +824.062 $ | +201,8 % | 1 |
| Lyell Immunopharma, Inc. | LYEL | → 0 | Neutral | 891.365 $ | +527.459 $ | +144,9 % | 1 |
| American Well Corp | AMWL | → 0 | Schwach | 478.061 $ | -212.989 $ | -30,8 % | 1 |
| Rani Therapeutics Holdings, Inc. | RANI | → 0 | Neutral | 101.554 $ | -2.865 $ | -2,7 % | 1 |
| STANDARD BIOTOOLS INC. | LAB | → 0 | Schwach | 21.470 $ | +1.652 $ | +8,3 % | 1 |
| 16.369.175 $ | +10.718.167 $ | +124,1 % | 8 | ||||